7:59 AM ET
8-K
Clinical Trial Data
Nektar Therapeutics Clinical Trial Data
Nektar Therapeutics announced long-term Phase 2b data for rezpegaldesleukin in patients with alopecia areata (REZOLVE-AA) and atopic dermatitis (REZOLVE-AD) at the EADV Congress 2026. The data demonstrated sustained hair regrowth and deepening of response even six months after treatment cessation, suggesting a differentiated regulatory T cell (Treg) mechanism compared to existing systemic therapies.
- Earnings call
- Oct 1, 2026, 3:00 PM ET